Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Bladder cancer at ASCO 2022: RC48 vedotin, chemoimmunotherapy

Jonathan Rosenberg • 5 Jun 2022
ASCO 2022
Bladder Cancer Genitourinary Cancer Disitamab Vedotin RC48 Vedotin

Jonathan E. Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses updates in the management of urothelial management presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, including the use of RC48 vedotin, a novel antibody-drug conjugate as well combination approaches with immune checkpoint inhibitors and chemotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Jonathan Rosenberg

0:57
PROs in advanced cisplatin-ineligible UC: first-line EV ± pembrolizumab
Jonathan Rosenberg • 7 Apr 2024
1:05
HRQoL in patients with previously treated advanced urothelial carcinoma from EV-301: EV vs chemo
Jonathan Rosenberg • 7 Apr 2024
2:15
LY4101174, a novel nectin-4-targeting ADC in solid tumors
Jonathan Rosenberg • 7 Apr 2024
0:44
Antibody-drug conjugates for advanced bladder cancer
Jonathan Rosenberg • 11 Sep 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals